Scarica l'app Stockscreener
124.82
0.37%
0.40
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$124.42
Aprire:
$124.33
Volume 24 ore:
3.34M
Relative Volume:
0.49
Capitalizzazione di mercato:
$217.17B
Reddito:
$43.11B
Utile/perdita netta:
$13.98B
Rapporto P/E:
15.64
EPS:
7.98
Flusso di cassa netto:
$6.66B
1 W Prestazione:
-5.02%
1M Prestazione:
-6.09%
6M Prestazione:
+6.03%
1 anno Prestazione:
+20.41%
Intervallo 1D:
$124.23
$126.38
Intervallo di 1 settimana:
$119.77
$133.03
Portata 52W:
$99.92
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Confronta ABT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
124.82 | 229.71B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.64 | 154.35B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
392.74 | 149.60B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.05 | 114.97B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.33 | 45.92B | 5.54B | 4.18B | 623.10M | 7.00 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Canada Oncology Market Outlook to 2033 - GlobeNewswire Inc.
Low-Calorie Food Market Top Companies StudyAbbott - openPR.com
What drives Abbott Laboratories stock priceDynamic portfolio growth - jammulinksnews.com
Abbott Laboratories: Hold Rating Amid Mixed Performance and Sector Challenges - TipRanks
Abbott Labs stock rating reiterated at Buy by UBS despite guidance cut - Investing.com India
Abbott Laboratories (ABT): I Am Very Upset With Abbott,” Says Jim Cramer - MSN
Abbott Laboratories falls after setting Q3 outlook below consensus - MSN
Abbott Laboratories Stock (ABT) Opinions on Q2 Earnings and Guidance Update - Quiver Quantitative
Abbott Laboratories (NYSE:ABT) Q2 2025 Earnings Call Transcript - MSN
Notable healthcare headlines for the week: Trump’s tariff threats, J&J, Abbott Laboratories and Sarepta in focus - MSN
What analysts say about Abbott Laboratories stockFree Wealth Management Insights - Autocar Professional
Is Abbott Laboratories (ABT) a Buy After the Earnings Selloff? - AInvest
Abbott Drops After Lowering Top End of Full-Year Guidance - MSN
Abbott Laboratories: A Medtech Titan Positioned for Growth in a Transformed Healthcare Landscape - AInvest
Abbott Laboratories Second Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Abbott Laboratories Sheds Nearly 5% On A Rare Guidance Miss - MSN
A Quick Look at Today's Ratings for Abbott Laboratories(ABT.US), With a Forecast Between $135 to $159 - 富途牛牛
Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX), Abbott Laboratories (ABT) and ANI Pharmaceuticals (ANIP) - The Globe and Mail
How Abbott Laboratories (ABT) Balances Innovation with Shareholder Payouts - MSN
Abbott Laboratories Stock Analysis and ForecastRobust investment performance - jammulinksnews.com
Abbott Laboratories Trading Volume Drops 27.57% to $24.28 Billion Ranking 25th - AInvest
Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield - MSN
Netflix, Abbott Labs Lead Friday’s Market Cap Stock Movers By Investing.com - Investing.com South Africa
Netflix, Abbott Labs Lead Friday’s Market Cap Stock Movers - Investing.com
Abbott Laboratories (NYSE:ABT) Releases Mixed Earnings Report - FXDailyReport.Com
Analysts defend Abbott Labs' stock after Thursday's 'too punitive' sell-off - CNBC
Scott+Scott Attorneys at Law LLP Alerts Investors There Is an Ongoing Securities Class Action Against Reckitt Benckiser Group PLC (OTC: RBGLY) - GlobeNewswire Inc.
Abbott Laboratories (ABT) Drops on Lower Full-Year Guidance - MSN
Abbott upgraded to Buy at Jefferies despite underwhelming outlook - MSN
Abbott Labs stock price target lowered to $155 at Citi on China diagnostics headwinds - Investing.com UK
Abbott Upgraded by Jefferies as Stock Selloff Seen as Overreaction - MSN
Abbott Laboratories (ABT) Stock: Q2 Beat Masks Challenges from COVID Test Decline, Tariffs, and China Pressure - CoinCentral
Abbott Leaps on Recent Stock Fluctuations - Baystreet.ca
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year? - Yahoo Finance
Down 9.0% in 4 Weeks, Here's Why Abbott (ABT) Looks Ripe for a Turnaround - Yahoo Finance
Buy Rating on Abbott Laboratories: Attractive Valuation Amid Growth Prospects and Market Overreaction - TipRanks
These Analysts Revise Their Forecasts On Abbott Following Q2 Results - Benzinga
Abbott Labs stock falls 8% as China headwinds prompt guidance cut - Investing.com Canada
A Quick Look at Today's Ratings for Abbott Laboratories(ABT.US), With a Forecast Between $140 to $153 - 富途牛牛
Abbott Laboratories: What's Behind The Q2 Earnings Slump? (NYSE:ABT) - Seeking Alpha
Abbott Labs stock falls 8% as China headwinds prompt guidance cut By Investing.com - Investing.com South Africa
Abbott upgraded after post-earnings selloff, hardware drag seen temporary - Investing.com
Abbott upgraded after post-earnings selloff, hardware drag seen temporary By Investing.com - Investing.com Canada
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):